shutterstock_1147238582_testing
Testing / Shutterstock.com
19 November 2019Americas

Roche buys fibrotic diseases biotech in $1.4bn deal

Switzerland-based  Roche has agreed to acquire  Promedior and its portfolio of molecules for serious fibrotic diseases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
31 October 2019   Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.
Americas
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Big Pharma
31 October 2019   Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.
Americas
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Big Pharma
31 October 2019   Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.
Americas
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.